Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

INNOVATE Global Phase 3 Trial
• INOVIO with Advaccine jointly conducting a global Phase 3 trial for INO-4800
• Healthy men and non-pregnant women 18 years and older (2.0 mg dose)
• Focus on countries currently underserved by vaccines, primarily in Latin
America, Asia and Africa
• Recently received regulatory approval to proceed from Brazil, Mexico, Colombia, and the Philippines, with other countries anticipated to follow

Heterologous Prime-Boost Trials
• Received regulatory allowance in China to conduct two clinical trials
investigating heterologous boosting with INO-4800
o Heterologousprime-boostsequentialimmunizationsusingINO-4800and
CoronaVac®
o Completed cross prime-boost pre-clinical animal tests; prime-boost
strategy stimulated high-level of humoral and cellular response

• The WHO also continues tracking 2 Variants of Interest (VOI) - Lambda and Mu - and at least 14 Variants Under Monitoring (VUM)1
• The US SARS-CoV-2 Interagency Group (SIG) now designates only Delta as a VOC2
• Delta is the most transmissible VOC discovered to date2
“The overarching goal is for COVID-19 vaccines to contribute significantly to the equitable protection and promotion of human well-being among all people of the world.”